-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

Benzinga·08/06/2026 17:46:05
Listen to the news
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.